Evidence map›Paper›PMID 37084859›Full record

ReviewPharmacological research2023

Discoveries and future significance of research into amyloid-beta/α7-containing nicotinic acetylcholine receptor (nAChR) interactions.

Paul Whiteaker, Andrew A George

Open access · goldAbstract readReview
In one paragraph

Review in Pharmacological research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. The Footprint ofCurrent Alzheimer research · 2025
    Pooled it
  2. Review
  3. Article
  4. Analogs of α-conotoxin PnIC selectively inhibit α7β2- over α7-only subtype nicotinic acetylcholine receptors via a novel allosteric mechanism.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Paul WhiteakerVirginia Commonwealth University School of Medicine, Department of Pharmacology and Toxicology, VCU Health Sciences Research Building, Box 980613, Richmond, VA 23298-0613, USA.
Andrew A GeorgeVirginia Commonwealth University School of Medicine, Department of Pharmacology and Toxicology, VCU Health Sciences Research Building, Box 980613, Richmond, VA 23298-0613, USA. Electronic address: Andrew.George@vcuhealth.org.
Virginia Commonwealth University · US

Funding

Relevance of α-Conotoxin MII Sensitive Nicotinic Receptor Subtypes to Nicotine AddictionR01DA042749 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI WHITEAKER, PAUL · 2017 to 2021
$2.8M
Prototoxin Effects on Nicotinic Receptor FunctionR01DA043567 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI MIWA, JULIE M., WHITEAKER, PAUL · 2018 to 2022
$2.4M
Characterization of amyloid-β:α7β2-nicotinic acetylcholine receptor interactions relevant to Alzheimer's diseaseR21AG067029 · NIA · VIRGINIA COMMONWEALTH UNIVERSITY · PI GEORGE, ANDREW ANTHONY, LUKAS, RONALD JOHN · 2020 to 2021
$423k
NIA NIH HHS R21 AG067029NIDA NIH HHS R01 DA042749NIDA NIH HHS R01 DA043567
6 · The paper itself

Abstract

Initiated by findings that Alzheimer's disease is associated with a profound loss of cholinergic markers in human brain, decades of studies have examined the interactions between specific subtypes of nicotinic acetylcholine receptors and amyloid-β [derived from the amyloid precursor protein (APP), which is cleaved to yield variable isoforms of amyloid-β]. We review the evolving understanding of amyloid-β's roles in Alzheimer's disease and pioneering studies that highlighted a role of nicotinic acetylcholine receptors in mediating important aspects of amyloid-β's effects. This review also surveys the current state of research into amyloid-β / nicotinic acetylcholine receptor interactions. The field has reached an exciting point in which common themes are emerging from the wide range of prior research and a range of accessible, relevant model systems are available to drive further progress. We highlight exciting new areas of inquiry and persistent challenges that need to be considered while conducting this research. Studies of amyloid-β and the nicotinic acetylcholine receptor populations that it interacts with provide opportunities for innovative basic and translational scientific breakthroughs related to nicotinic receptor biology, Alzheimer's disease, and cholinergic contributions to cognition more broadly.

Indexed as

Alzheimer DiseaseReceptors, Nicotinicalpha7 Nicotinic Acetylcholine ReceptorAmyloid beta-PeptidesAnimalsCholinergic AgentsDisease Models, AnimalHumansalpha7 Nicotinic Acetylcholine ReceptorAmyloid beta-PeptidesCholinergic AgentsReceptors, NicotinicAlzheimer’s diseaseCholinergic neuronsMemoryNeuronal hyperexcitationNicotinic receptorsOligomeric amyloid-beta

Identifiers

PMID37084859
PMCPMC10228377
OpenAlexW4366526189

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.